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a b s t r a c t
The microRNA (miRNA) mdv1-miR-M4, a functional miR-155 ortholog encoded by oncogenic Marek's
disease virus (MDV), has previously been suggested to be involved in MDV pathogenesis. Using
the technique of bacterial artiﬁcial chromosome mutagenesis, we have presently evaluated the potential
role of mdv1-miR-M4 in the oncogenesis of the very virulent (vv) MDV strain GX0101. Unexpectedly,
deletions of the Meq-cluster or mdv1-miR-M4 alone from the viral genome strongly decreased rather
than abolished its oncogenicity. Compared to GX0101, mortalities of mutants GXΔmiR-M4 and
GXΔMeq-miRs were reduced from 100% to 18% and 4%, coupled with the gross tumor incidence
reduction from 28% to 22% and 8%, respectively. Our data suggests that the mdv1-miR-M4 is possibly an
important regulator in the development of Marek's disease (MD) lymphomas but is not essential for the
oncogenicity of vvMDV. In addition, some of the other Meq-clustered miRNAs may also play potentially
critical roles in vvMDV induction of lymphomas.
& 2013 The Authors. Published by Elsevier Inc.
Introduction
The discovery of microRNA (miRNA) can be seen as one of the
more important discoveries in the life sciences during the past
2 decades. These small non-coding RNAs (sncRNAs) play important
post-transcriptional regulatory roles in various cellular processes,
including development, differentiation, and all aspects of cancer
biology (Bartel, 2004; Filipowicz et al., 2008; Lee and Dutta, 2009).
Thousands of miRNAs have been identiﬁed in animals and plants,
and even in viruses. MiRNAs encoded by diverse virus families, such
as Epstein–Barr virus (EBV), Kaposi's sarcoma-associated herpes-
virus (KSHV), and Marek's disease virus (MDV), are found to be
involved in their pathogenicity, especially in the tumorigenicity
(Boss et al., 2009; Morgan and Burnside, 2011; Grundhoff and
Sullivan, 2011; Kincaid and Sullivan, 2012). Phylogenetically, MDV
is classiﬁed into the subfamily Alphaherpesvirinae (Davison et al.,
2009). As one of the most potent oncogenic herpesvirus, the
infection of MDV can cause a highly contagious, lymphoproliferative
disorder, and neoplastic disease of poultry named as Marek's
disease (MD) (Witter and Schat, 2003). Since it was identiﬁed as a
pathogen, three distinct serotypes, serotype 1 (MDV-1), serotype
2 (MDV-2), and serotype 3 (herpesvirus of turkeys, HVT), have been
characterized but recently reclassiﬁed as species of Gallid herpes-
virus 2 (GaHV2), Gallid herpesvirus 3 (GaHV3), and Meleagrid
herpesvirus 1 (MeHV1), respectively (Witter and Schat, 2003;
Davison et al., 2009). The virulent strains of GaHV2 establish and
maintain latent infections in their natural hosts and may ﬁnally
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cause a rapid onset aggressive T-cell lymphoma (Nair and Kung,
2004). MD is considered to be an excellent biomedical model for
the study of virus-induced lymphoma (Osterrieder et al., 2006) and
provided the ﬁrst demonstration of the efﬁcacy of anti-viral
vaccination in the control of cancer. The molecular mechanisms of
MDV pathogenicity and particularly with respect to the oncogenesis
have historically been an attractive focus of research.
In recent years, it has been suggested that among the more than
100 viral genes, the GaHV2-speciﬁc gene Meq (MDV EcoRI-Q),
which encodes the basic leucine zipper protein, is the major
oncogene while the other genes, including the BamH I-H family of
transcripts, phosphoprotein 38 (pp38), viral interleukin-8 (vIL-8),
ICP4-related transcripts (R-ICP4), and MDV-encoded telomerase
RNA, are associated with MDV pathogenicity (Burgess, 2004).
However a large number of viral miRNAs have been found to be
encoded in the genomes of all three serotypes of MDV (Burnside
et al., 2006; Yao et al., 2007, 2008, 2009; Waidner et al., 2009).
Although MDV-encoded miRNAs do not show conservation in
sequence, their genomic location in the long or short repeat
(RL/RS) regions is conserved in all three serotypes of MDV. MDV
genomes are primarily composed of a ‘unique long region’ (UL) and
a ‘unique short region’ (US), ﬂanked by inverted repeats namely as
‘terminal and internal repeat long regions’ (TRL/IRL) and ‘internal
and terminal repeat short regions’ (IRS/TRS) (Cebrian et al., 1982).
The genes encoded by the UL and US regions are highly conserved
among herpesviruses whereas virus-speciﬁc genes are mainly
located in the inverted repeat regions (Osterrieder et al., 2006).
Thus the highly conserved genomic location of the viral miRNA
implies that they have important functions.
In the viral genome of GaHV2 as shown in Fig. 1a and b, all
of the virus-encoded miRNAs, each presenting as two identical
copies, are focused in three gene clusters, namely Meq-cluster, mid-
cluster, and LAT-cluster (Luo et al., 2010). The Meq-clustered
miRNAs, upstream from the meq oncogene, are mdv1-miR-M9,
mdv1-miR-M5, mdv1-miR-M12, mdv1-miR-M3, mdv1-miR-M2,
and mdv1-miR-M4 (Burnside et al., 2006; Yao et al., 2008). Intervals
between these miRNA precursors are short, less than 220 nt. A
recent report has shown that these miRNAs are located in the ﬁrst
intron of the transcripts covering the IRL/TRL region, and their
transcription is driven by a single promoter, prmiRM9M4, under
two distinct transcriptional models during different infection phases
(Coupeau et al., 2012). The mid-clustered miRNAs, including mdv1-
miR-M11, mdv1-miR-M32, and mdv1-miR-M1, are embedded
within the open reading frame (ORF) of the L1/LORF5a transcript
as well as within the intron of the splice variant Meq-sp, located
downstream of the Meq-cluster and upstream of the LAT-cluster.
Other GaHV2-encoded miRNAs, such as mdv1-miR-M8, mdv1-miR-
M13, mdv1-miR-M6, mdv1-miR-M7 and mdv1-miR M10, are
located in the large intron of the latency-associated transcript
(LAT) and comprise the LAT-cluster (Burnside et al., 2006; Yao
et al., 2008). Compared to Meq-clustered miRNAs, intervals
between LAT-clustered miRNA precursors are shorter, with some
overlaps. A p53-dependent promoter, which has no consensus core
promoter element but contains at least two 60-bp tandem repeats
harboring a p53-response element, has been found to drive the
transcription of LAT-clustered miRNAs (Stik et al., 2010).
MiRNA expression signatures in many cancers have been char-
acterized and further increased our understanding of the connec-
tions between miRNA and tumorigenesis (Calin and Croce, 2006). For
GaHV2-encoded miRNAs, studies focusing on the miRNA expressions
in virus-infected chicken embryo ﬁbroblast (CEF) cultures, virus-
transformed cell lines, and virus-caused splenic tumors have shown
Fig. 1. Schematics of the viral genome of GaHV2 (A) and viral miRNAs located in MDV strains GX0101 (B), GXΔMeq-miRs (C), and GXΔmiR-M4 (D). Relative genomic
locations of viral miRNAs at two identical genomic loci are shown by solid or dashed lines. MiRNA precursors (pre-miR) and miRNA gene clusters (miR-cluster) are shown by
green hairpins or hollow arrows, respectively. Mature miRNAs (mat-miR), passenger miRNAs (miRNAn) and unstable miRNAs (unstable-miR) are shown by red, blue or gray
strands in the stems of green hairpins, respectively. As for the deleted miRNAs (miR-deleted), they are shown by dashed hairpins without strands in the stems.
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that most viral miRNAs are expressed at higher levels in splenic
tumors and a T-lymphoma cell line than in CEFs (Burnside et al.,
2006; Yao et al., 2008). In vivo expression proﬁles have shown that
only a subset of miRNAs is differentially and tissue-speciﬁcally
expressed during different phases of the developing disease, suggest-
ing differing regulatory roles in MDV pathogenesis (Luo et al., 2011).
Although sequences are highly conserved among oncogenic GaHV2
strains of differing virulence, the Meq-clustered miRNAs are
expressed at higher levels in lymphomas produced by very virulent
plus (vvþ) MDV than those produced by a less very virulent (vv)
MDV strain, whereas the LAT-cluster miRNAs expression is equal
(Morgan et al., 2008), implying that the Meq-clustered miRNAs may
have a more signiﬁcant role in MD oncogenesis.
To date, more than 450 miRNAs have been reported in 35 various
viruses (Kincaid and Sullivan, 2012). However, the biological functions
of most viral miRNAs, including GaHV2-encoded miRNAs, remain
unresolved due to the difﬁculties in identifying mRNA targets and
their associated signaling pathways. Recently, the mdv1-miR-M7-5p
has been veriﬁed to target the immediate-early genes ICP4 and ICP27,
suggesting that LAT-clustered miRNAs possibly contribute to establish
and/or maintain latency (Strassheim et al., 2012). As for Meq-clustered
miRNAs, several studies have shown that some of them are involved in
MDV oncogenesis. The miRNA mdv1-miR-M3-5p was found to target
and downregulate expression of Smad2, a critical component in the
transforming growth factor beta (TGF-β) signal pathway, potentially
creating a cellular environment beneﬁcial to viral latency and onco-
genesis (Xu et al., 2011). The miRNAmdv1-miR-M4-5p, similarly to the
KSHV-encoded miR-K12-11 (Gottwein et al., 2007), has been char-
acterized as a functional ortholog of cellular miR-155 and speciﬁcally
inhibits the translation of viral proteins involved in the cleavage/
packaging of herpesvirus DNA (Zhao et al., 2009; Muylkens et al.,
2010). Since miR-155 is a host-encoded miRNA associated with several
cancers (Tili et al., 2009; Faraoni et al., 2009) and involved in EBV-
induced transformation (Yin et al., 2010), mdv1-miR-M4-5p was
hypothesized to play a critical role in MDV oncogenesis. Using a
virulent (v) MDV strain pRB-1B5 and a series of mutant viruses
modiﬁed by the reverse genetics technique of infectious bacterial
artiﬁcial chromosome (BAC) clone, a recent study has reported that
the deletion of mdv1-miR-M4 from the viral genome could abolish the
oncogenicity of the virus (Zhao et al., 2011).
However in recent years, increase in virulence of oncogenic MDVs
has occurred and the GaHV2 isolates have been grouped into four
further pathotypes designated as classic or mild (m) MDV, vMDV,
vvMDV, and vvþMDVs (Witter, 1997). Whether the miR-155 ortho-
logs encoded by distinct pathotypes of oncogenic MDVs play com-
pletely same, similar, or different roles in the induction of MD
lymphomas remains unknown. Herein, in order to investigate the
biological role of mdv1-miR-M4 in vvMDV oncogenesis, we have
constructed the Meq-cluster-deleted and mdv1-miR-M4-deleted
viruses, namely GXΔMeq-miRs or GXΔmiR-M4 as demonstrated
in Fig. 1c and d, using BAC mutagenesis based on the full-length
infectious BAC clone of the vvMDV strain GX0101 (Sun et al., 2009,
2010; Cui et al., 2010; Su et al., 2012). Surprisingly, our data demon-
strates that the deletions of the Meq-cluster or mdv1-miR-M4 alone
from the GX0101 genome signiﬁcantly decreased but did not abolish
its oncogenicity. It suggests that the virus-encoded miR-155 ortholog
is not essential for the oncogenicity of vvMDV but contributes to the
viral lethality and tumor incidence. More studies need to be
performed to reveal the fundamental molecular determinants that
trigger the lymphomas induced by highly oncogenic MDVs.
Results
Veriﬁcation of the BAC clones of GXΔMeq-miRs and GXΔmiR-M4
To investigate the roles of the Meq-clustered miRNAs and
mdv1-miR-M4 involved in MDV pathogenesis, two BAC clones
with the corresponding deletions, as shown in Fig. 1c and d, were
constructed by two rounds of BAC mutagenesis based on the full-
length infectious BAC clone of the vvMDV strain GX0101. The
deletion of the Meq-clustered miRNAs and mdv1-miR-M4-located
regions and existing of the recombinant BAC DNAs were veriﬁed
by PCR analysis using puriﬁed GX0101-BAC, GXΔMeq-miRs-BAC
and GXΔmiR-M4-BAC as templates, with different speciﬁc primer
pairs, as listed in Table S1. The agarose gel electrophoresis of PCR
products showed that identical products of all three MDV genes,
including Meq, pp38 and gB, were generated by PCR on all the
three templates, demonstrating that the mutagenesis steps did not
Fig. 2. Comparisons of the PCR products ampliﬁed from GX0101 and miRNA-
deleted viruses. (A) and (B) PCR analysis using the DNAs of GX0101-BAC, GXΔMeq-
miRs-BAC or GXΔmiR-M4-BAC as templates; and (C) and (D) PCR analysis using the
viral genomic DNAs of GX0101, GXΔMeq-miRs or GXΔmiR-M4 viruses as tem-
plates. Primer pairs with different usages used for performing the PCR analysis and
their corresponding amplicons are listed in Table S1. Meq, MDV EcoRI-Q gene; pp38,
phosphorylated protein 38 gene; gB, glycoprotein B gene; Kana, kanamycin gene;
primiR, primary miRNA; pre-miR, miRNA precursor; and OVO, chicken ovotrans-
ferrin gene.
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affect the structure of surrounding genes of the recombinant BACs
(Fig. 2a and b). The presences of bands of both Kana and primiR
fragments indicate the chimeric regions containing a kanamycin
cassette in the ﬁnal mutants GXΔMeq-miRs-BAC and GXΔmiR-
M4-BAC compared to GX0101-BAC, whereas the changed bands
of pre-miR fragments demonstrate the deletions of miRNA genes
from the two identical genomic loci in TRL and IRL regions of both
GXΔMeq-miRs-BAC and GXΔmiR-M4-BAC DNAs. The deletions of
the Meq-cluster or mdv1-miR-M4 genes from these clones were
further conﬁrmed by DNA sequence analysis (Table S2).
Characterization of the reconstituted viruses and miRNA expression
GXΔMeq-miRs and GXΔmiR-M4 viruses were reconstituted by
transfection of BAC DNAs into CEFs. Characteristic MDV plaques
were visible at 5–7 days post-transfection. Morphology of the
plaques produced by the two rescued viruses was indistinguish-
able from each other, and from those produced by the parental
virus GX0101. As shown in Fig. 2c and d, and Table S2, both PCR
analysis using the rescued viral genomic DNAs as templates and
subsequent sequence analysis gave exactly the same results to
those performed using BAC DNAs as templates. Speciﬁc staining
of the viral plaques but not control non-transfected CEFs with
MDV pp38-speciﬁc monoclonal antibody, further conﬁrmed the
speciﬁcity of the viral plaques (Fig. 3a). The expressions of Meq-
clustered miRNAs in reconstituted viruses were determined by
northern blotting analysis using the [γ-32P]ATP-labeled oligonu-
cleotides listed in Table S1. As shown in Fig. 3b, both precursors
and mature miRNAs (pre-miR and mat-miR) of corresponding
Meq-clustered miRNAs or mdv1-miR-M4 were detected in CEFs
infected with the parental virus GX0101 while in the viruses
GXΔMeq-miRs or GXΔmiR-M4-infected CEFs and mock CEFs,
no expression of corresponding miRNAs was observed, further
conﬁrming the successful deletions of miRNA genes from GX0101
genome.
In vitro and in vivo growth kinetics of GXΔMeq-miRs and GXΔmiR-
M4 viruses
To investigate the inﬂuence of miRNA deletions on the pro-
liferation of vvMDV, a real-time qPCR was performed and the
in vitro growth kinetics showed very similar replication kinetics
for both the parent GX0101 and mutant viruses GXΔMeq-miRs or
GXΔmiR-M4 (Fig. 4a and b), indicating that miRNAs mdv1-miR-
M4 or the other Meq-clustered miRNAs are not essential for
replication of MDV in vitro. Similarly, the in vivo growth kinetics
also showed that the Meq-clustered miRNAs are not essential for
replication of MDV in vivo. There was however, some effect of the
deletions in the Meq-cluster locus affecting the viral replication
in vivo. As shown in Fig. 4c and d, GX0101 virus was detected in
infected birds as early as 1 dpi and its growth rate increased
during the following 3 weeks, peaking at about 30 dpi, and then
declining rapidly during the last month of the experiment. In
contrast to GX0101, the mutant viruses GXΔmiR-M4 showed a low
growth until about 75 dpi when there was an abrupt transient
increase, whereas GXΔMeq-miRs was maximal at about 14 dpi
but then replicated at a low level, declining slowly over the
remaining experimental time period.
Inﬂuence of the deletion of miRNA genes on growth rates of birds
To compare the pathogenicity of mutant viruses with their
parental virus, we examined the growth rates of infected birds.
Three experimental groups, each consisting of 80 1-day-old
chickens, were separately challenged with GX0101, GXΔMeq-
miRs or GXΔmiR-M4 viruses by abdominal cavity inoculation
while the negative control birds were inoculated with an equal
volume of uninfected CEFs. No difference in body weight of birds
in all the four groups was observed in the ﬁrst week post-
challenge. Compared to the uninfected controls, GX0101 strongly
inhibited the growth rates of infected birds after 14 dpi. As shown
in Fig. 5, their body weights were lower (especially at 14, 21, and
30 dpi with po0.05) than that of the GXΔMeq-miRs, GXΔmiR-
M4 or CEF-inoculated birds. However compared to the negative
control group, the growth rates in GXΔMeq-miRs or GXΔmiR-
M4-inoculated birds were not obviously inﬂuenced during the
whole experimental time period of 90 days.
Inﬂuence of the deletion of miRNA genes on immune organs of birds
As demonstrated in Fig. 6, for the ﬁrst week post-challenge,
no difference of the average bursa/body weight or thymus/body
weight ratios of the birds in each group challenged with MDVs or
CEFs was observed. However, at 14 and 21 dpi, ratios of both bursa
and thymus over body weight of birds inoculated with the
parental GX0101 or the mutant viruses were signiﬁcantly lower
(po0.05) than that of the control birds. The bursa/body weight
ratio was signiﬁcantly different (po0.05) between the parental
virus and both of the mutant viruses at 21 dpi.
Fig. 3. Characterization of miRNA-deleted MDV viruses. (A) Plaques of MDV
GX0101, GXΔMeq-miRs and GXΔmiR-M4 in IFA under a ﬂuorescence microscope.
Non-infected CEFs are used as control. (B) Northern blotting analysis of the
expressions of the Meq-clustered miRNAs in CEFs infected by distinct MDVs. Mixed
probes #15–19 and unique probe #15, listed in Table S1, were used for detecting
the miRNA expressions in CEFs infected by GXΔMeq-miRs or GXΔmiR-M4,
respectively. RNAs from GX0101-infected or uninfected CEFs serve as controls.
Probe #20 speciﬁc for U6 snRNA serves as the inner control.
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Pathogenicities of parental GX0101 and the derivative mutant viruses
Post-challenge, the GX0101-challenged group developed MD
rapidly with most of the birds showing classic clinical signs and
mortalities starting as early as 7 dpi and continuing at an increasing
rate until all had died by 75 dpi (Fig. 7). By comparison birds
inoculated with GXΔmiR-M4 or GXΔMeq-miRs viruses did not show
signs of MD until about 30 dpi and exhibited low mortality (Table 1)
so that at 90 dpi, while there were no surviving birds from the
GX0101-challenged group, 82% and 96% of the birds infected with
GXΔmiR-M4 or GXΔMeq-miR remained alive (Fig. 7). By 75 dpi when
all of the GX0101 infected birds had died, 28%, 4% and 2% of birds
demonstrated gross tumors in different tissues or organs (mainly
concentrated in spleens, livers and proventriculus) in groups infected
with GX0101, GXΔmiR-M4 or GXΔMeq-miRs viruses, respectively.
By 90 dpi this had risen to 22% and 8% in the GXΔmiR-M4 and
GXΔMeq-miR infected groups, respectively. These results showed that
the mortalities and oncogenicities of the mutant viruses GXΔmiR-M4
and GXΔMeq-miRs were strongly suppressed when compared to the
parental GX0101 virus.
Fig. 4. In vitro and in vivo growth kinetics of MDV strains GX0101, GXΔMeq-miRs and GXΔmiR-M4. Growth rates of the parental virus and its mutants measured from the
viral genome copy numbers per 100,000 cells were determined using a real-time qPCR on DNA extracted from CEFs (A) and (B) or birds (C) and (D) sampled at various time
points after virus infection or inoculation. For GX0101 group, there is no data available at time points of 75 or 90 dpi because all the birds had died before 75 dpi. (A) Meq in
vitro, (B) gB in vitro, (C) Meq in vivo and (D) gB in vivo.
Fig. 5. Comparisons of the average body weights of birds post-challenge with distinct MDVs. For each group, the body weights of six randomly selected live birds were
measured at any time point post-infection. The black or red stars indicate signiﬁcant difference (po0.05) to CEFs and GX0101 controls, respectively. There is no data
applicable for GX0101 at 75 and 90 dpi due to the death of all birds.
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Pathological lesions and tumorigenesis induced by MDVs
To determine the correlations between the deletion of viral
miRNA genes and the processes of tumorigenesis, three birds
showing no gross organic tumors at 30, 60 and 90 dpi from each
group inoculated with GX0101, GXΔmiR-M4 or GXΔMeq-miRs
viruses were randomly selected and their livers examined histo-
logically. As demonstrated in Table 2, tumor foci were ﬁrst
observed in the livers of a few birds infected with either GX0101
or GXΔmiR-M4 at 30 dpi while for those inoculated with
GXΔMeq-miRs, no tumors were observed. Subsequently, the
positive rates of tumorigenesis in each group increased and for
that of GX0101 and GXΔmiR-M4, it achieved 100% at 60 dpi or
90 dpi, respectively, while for the group of GXΔMeq-miRs, the
microscopic tumor incidence in infected chickens is apparently
Fig. 6. Comparisons of the average bursa (A) and thymus (B) over body weight
ratios of each group challenged with MDVs. For each group, the body weights,
bursa weights and thymus weights of six randomly selected birds were measured
at different time points post-challenge. The black or red stars indicate signiﬁcant
difference (po0.05) to CEFs and GX0101 controls, respectively.
Fig. 7. Survival curves of the birds challenged with MDV strains GX0101, GXΔMeq-
miRs or GXΔmiR-M4 during the 90 days experimental time period. For the
experimental groups, each consisting of 80 1-day-old birds, were separately
challenged with CEFs containing 2000 PFUs of MDV viruses by abdominal cavity
inoculation. A fourth group of birds (n¼80) inoculated with an equal volume of
mock infected CEFs serves as negative controls.
Table 1
Accumulated death and gross tumors occuring in chickens challenged by MDV-1
strains GX0101 and its miRNA-deleted mutants at different time points post-
infection.
Time point
(dpi)
Strain and
category
GX0101 GXΔmiR-
M4
GXΔMeq-
miRs
Mock
CEFs
1 Deaths – – – –
Mortality – – – –
Gross tumors – – – –
Tumor incidence – – – –
7 Deaths – – – –
Mortality 2% – – –
Gross tumors – – – –
Tumor incidence – – – –
14 Deaths 2 – – –
Mortality 4% – – –
Gross tumors 1 – – –
Tumor incidence 2% – – –
21 Deaths 14 1 – –
Mortality 28% 2% – –
Gross tumors 3 – – –
Tumor incidence 6% – – –
30 Deaths 38 2 – –
Mortality 76% 4% – –
Gross tumors 9 – – –
Tumor incidence 18% – – –
45 Deaths 43 4 1 –
Mortality 86% 8% 2% –
Gross tumors 10 – – –
Tumor incidence 20% – – –
60 Deaths 49 4 2 –
Mortality 98% 5% 4% –
Gross tumors 10 – 1 –
Tumor incidence 20% – 2% –
75 Deaths 50 6 2 –
Mortality 100% 12% 4% –
Gross tumors 14 2 1 –
Tumor incidence 28% 4% 2% –
90 Deaths / 9 2 –
Mortality / 18% 4% –
Gross tumors / 11 4 –
Tumor incidence / 22% 8% –
Total of 50 birds in each group.
“-” means that no death or gross tumors were observed at corresponding time
points post-challenge.
“/” means that there is no data applicable due to the death of all GX0101-
challenged chickens before 75 dpi.
Table 2
Numbers of chickens showing microscopic tumors in the liver.
Group/strain Tumor incidencea
30 dpi 60 dpi 90 dpi
GX0101 1/3 (33.3%) 3/3 (100.0%) /
GXΔmiR-M4 1/3 (33.3%) 1/3 (33.3%) 3/3 (100.0%)
GXΔMeq-miRs 0/3 (0.00%) 1/3 (33.3%) 1/3 (33.3%)
Mock CEFs 0/3 (0.00%) 0/3 (0.00%) 0/3 (0.00%)
“/” means that there is no data applicable due to the death of all GX0101-
challenged chickens before 75 dpi.
a For each group, three birds without gross organic tumors were randomly
selected for preparing the pathologic sections at 30, 60 and 90 dpi.
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lower than that of GXΔmiR-M4-infected birds at 90 dpi. Histolo-
gical lesions in livers of the birds infected with GX0101 or mutant
viruses at 60 dpi are demonstrated in Fig. 8. Numbers of tumor foci
in the positive birds induced by MDVs were calculated but no
signiﬁcant differences were found among the parental and mutant
viruses (data not shown). During the whole experimental time
period, no tumorigenesis was recorded in the control group. These
results further indicate that the oncogenicities of the mutant
viruses GXΔmiR-M4 and GXΔMeq-miRs were depressed, but
not abolished compared to that of parental GX0101 virus.
Discussion
Although multiple herpesvirus-encoded miRNAs were found
to be abundantly expressed during lytic, replicative, latent and
even tumorigenic stages of disease, the characterization of their
biological functions is still challenging and only a few have been
preliminarily identiﬁed (Boss et al., 2009; Grundhoff and Sullivan,
2011; Kincaid and Sullivan, 2012). Oncogenic MDVs will ultimately
induce tumors in their natural hosts and this can be prevented
by vaccination. Thus MDV infection is considered to be an ideal
biomedical model for investigating the biology, genetics, and
immunology of viral tumorigenesis (Osterrieder et al., 2006).
In recent years, new experimental techniques have facilitated the
use of BAC or cosmid vectors for the manipulation of the large
herpesvirus genomes, including that of MDV, for further investi-
gating its pathogenicity and for the production of vaccines
(Schumacher et al., 2000; Petherbridge et al., 2003, 2004; Sun
et al., 2009, 2010). Along with the establishment of strategies for
the identiﬁcation of mRNA targets, the application of BAC techni-
ques and recE/T homologous recombination in research on MD
pathogenesis, it is expected that further understanding of the
biological functions of MDV-encoded miRNAs will naturally follow.
One of the highest expressed viral miRNAs in vivo (Morgan
et al., 2008; Luo et al., 2011), mdv1-miR-M4, has been character-
ized as a functional ortholog of the cellular miR-155 and has been
preliminarily implicated in MDV oncogenesis (Zhao et al., 2009;
Muylkens et al., 2010). It has been shown recently that the
deletion of mdv1-miR-M4 from the viral genome of an infectious
BAC clone pRB-1B5 abolished the oncogenicity of the virus
(Zhao et al., 2011). However, our present work also based on BAC
mutagenesis of an infectious BAC clone derived from the vvMDV
strain GX0101 showed that deletions of the Meq-cluster or mdv1-
miR-M4 alone from the viral genome strongly decreased rather
than abolished the oncogenicity of this strain. Compared to the
parental virus GX0101, mortalities of the mutant viruses GXΔmiR-
M4 and GXΔMeq-miRs were reduced from 100% to 18% and 4%,
respectively. As for the oncogenicity, a similar phenomenon was
observed in that in GX0101, GXΔmiR-M4 and GXΔMeq-miRs-
challenged birds, showed a gross tumor incidence reduction from
28% to 22% and 8%, respectively. Although both of the miRNA-
deletions interrupted the overlapping R-LORF8 gene, a latest
report has shown that this gene is not a major determinant of
oncogenicity (Zhao et al., 2011). The difference in the oncogenic
phenotypes of mutant viruses produced from pRB-1B5 and
Fig. 8. Pathologic lesions and tumorigenesis in the livers of birds challenged with MDV GX0101, GXΔMeq-miRs or GXΔmiR-M4 at 60 dpi. All the observations at the time
points of 30, 60, and 90 dpi were repeated independently in triplicate on three birds from each group (one representative repeat is shown). Tumor foci are shown by black
arrows (original magniﬁcation 200 ).
Z.-H. Yu et al. / Virology 448 (2014) 55–64 61
GX0101 is possibly consequences of the differences in the adopted
experimental protocols. Firstly, higher infecting doses of GX0101
and its mutant MDVs were used (2000 PFU for each bird), which
possibly caused a more rapid onset and progression of disease.
Secondly, for comparing the pathogenicities and oncogenicities
between parental GX0101 and its mutant viruses, the experimen-
tal groups contained larger numbers of birds (n¼80), and thirdly a
longer experimental time period of 90 days was used.
Except for the possibilities discussed above, differences in the
virulence between the parental viruses GX0101 and pRB-1B5 may
be mainly responsible for the distinct pathogenic pathotypes of
their miRNA-deleted mutants. GX0101 is a highly oncogenic strain
of the vvMDV and the infectious BAC clone of GX0101, the parent
used in the present study, retained its original pathogenicity and
oncogenicity (Sun et al., 2009; Cui et al., 2010). In contrast, pRB-
1B5 although it was also an infectious BAC clone its pathogenicity
was signiﬁcant lower (po0.0001) than that of the original virus
(Petherbridge et al., 2004; Zhao et al., 2008, 2011). The ﬁnal
possibility which cannot be excluded is a differential susceptibility
of chicken lines, white Leghorn used presently and P-line (MHC
type B19/B19) used previously (Zhao et al., 2011), to the parental
MDV strains and mutants derived from GX0101 or pRB-1B. To test
this hypothesis, crossover experiments using these two chicken
lines for the infections of GX0101 or pRB-1B5 and their mutants
deserve to be performed in future works. Whatever the reasons
behind the differences are, data obtained from mutant MDVs
from both vMDV and vvMDV strains suggests that mdv1-miR-M4
plays an important potential role in MDV oncogenesis but for
vvMDV, the virus encoded miR-155 ortholog is not essential for
its oncogenicity and seems to contribute to the viral lethality
and tumor incidence. Weather the signiﬁcant decrease in patho-
genicity and oncogenicity is due to the reduction of tumorigen-
esis processes that regulated by viral miRNAs remains to be
uncovered.
For vvMDV strain GX0101 used in this study, the mutant virus
with the deletion of all Meq-clustered miRNAs, GXΔMeq-miRs, had
signiﬁcantly lower pathogenicity and oncogenicity than that of
GXΔmiR-M4 with the deletion of only mdv1-miR-M4 within the
Meq-cluster, implying that the other miRNAs of the Meq-cluster
may play similar important role in tumorigenesis. Mdv1-miR-M3-
5p, another miRNA encoded within the Meq-cluster, has been
suggested to contribute to the induction of MD lymphomas by
targeting Smad2 of the TGF-β pathway (Xu et al., 2011), an
important signal pathway associated with lymphomagenesis (Rai
et al., 2010). Except for the previously reported cellular and viral
target genes (Muylkens et al., 2010), recent studies in our laboratory
have found that mdv1-miR-M4-5p also regulates the TGF-β path-
way by targeting LTBP1, the latent transforming growth factor-β
binding protein 1 (in preparation). This suggests that to date, at least
two Meq-clustered miRNAs have been found to simultaneously
regulate the MDV tumorigenesis by targeting diverse genes in the
same signaling network. Similarly to mdv1-miR-M4-5p and mdv1-
miR-M3-5p, the Meq-clustered mdv1-miR-M12-3p has also been
previously characterized as an early-expressed miRNA during dif-
ferent phases of the developing disease (Luo et al., 2011). Whether
or not these other miRNAs encoded in the Meq-cluster or the other
two clusters play a part in the induction of lymphomas remains to
be further studied.
During past several decades, possibly due to selection pressure
from vaccination, the virulence of oncogenic MDVs has been seen
to have increased (Witter, 1997). The reasons for the observed
enhanced virulence of ﬁeld MDVs remain unknown. During latent
and lytic phases, the genes of meq and Meq-clustered miRNAs
have been found to be expressed under two different transcrip-
tional processes (Coupeau et al., 2012). In lymphomas produced by
vvþMDV strain 615K, the Meq-clustered miRNAs have been found
to be expressed at higher levels than by vvMDV strain RB-1B,
although these viral miRNAs have conserved sequences among
MDV strains of different virulences (Morgan et al., 2008). Our
present studies, together with a previous report (Zhao et al., 2011),
showed that the Meq-clustered miRNAs possibly play differential
roles in both the pathogenicity and oncogenicity among vMDV and
vvMDV strains. This leads us to speculate that the virus-encoded
miRNAs themselves and/or their potential transcriptional control
mechanisms possibly contribute to MDV virulence enhancement.
To elucidate such a suggestion, experiments using different strains
of mMDV, vMDV, vvMDV and vvþMDV will need to be performed
in the future.
Materials and methods
Viruses
MDV GX0101 is a ﬁeld strain isolated from a layer farm in
Guangxi Province of China (Cui et al., 2010; Su et al., 2012).
Infectious BAC-derived GX0101 virus was previously obtained by
transfection of the BAC DNA into CEF cultures (Sun et al., 2009,
2010).
Chickens
Experiments were conducted in commercial speciﬁc-pathogen-
free (SPF) white Leghorn chickens (Jinan SPF Egg & Poultry Co. Ltd.,
China) that were maintained in isolators with ﬁltered air of
positive pressure in an SPF animal facility (LuoYang Pu-Like Bio-
Engineering Co., Ltd., China).
Construction of GXΔMeq-miRs-BAC and GXΔmiR-M4-BAC
The steps used for the construction of the Meq-cluster and
mdv1-miR-M4-deleted GX0101-BAC clones, namely GXΔMeq-
miRs-BAC and GXΔmiR-M4-BAC respectively, are performed as
described previously (Sun et al., 2010). Brieﬂy, Escherichia coli
(E. coli) EL250 cells transformed with GX0101-BAC containing the
whole genome of GX0101 were prepared by inoculating a fresh
overnight culture into 10 mL of Luria–Bertani (LB) medium con-
taining chloramphenicol (25 mg/mL) until an optical density at
600 nm of 0.5 was attained. Then, expression of recE, recT, and λ
gam was induced by incubating at 42 1C for 15 min and collected
for preparing electrocompetent cells by a standard protocol
(Muyrers et al., 1999; Narayanan et al., 1999). KanaR cassettes
ﬂanked by FRT sites were ampliﬁed using primers miRMeqF-
KanaR, miRMeqR-KanaR, miR4F-KanaR, and miR4R-KanaR (primer
pair #1 and #2, Table S1) from pKD13 (Datsenko and Wanner,
2000). After digesting with Dpn I to remove the residual pKD13
template, the PCR products were puriﬁed following electrophor-
esis using the Gel Extraction Kit (OMEGA, #D2500-01). About
300 ng of the PCR products were electroporated into 50 mL of
electrocompetent EL250 cells harboring the GX0101-BAC using
standard electroporation parameters (2.0 KV, 200Ω and 25 mF).
After electroporation, the cells were grown in 1 mL of SOC
medium for 2 h and spread onto LB agar plates containing
chloramphenicol (25 mg/mL) and kanamycin (50 mg/mL). Resistant
colonies were picked and grown in liquid LB medium. Excision of
the KanaR cassettes was carried out by induction of FLPe recombi-
nase by adding 0.1% arabinose into the medium. To delete the
second miRNA allele from the TRL or IRL regions, another round of
BAC mutagenesis was performed in the same way. Finally, the
EL250 cells harboring GXΔMeq-miRs-BAC or GXΔmiR-M4-BAC
were grown and the BAC DNA was prepared using Plasmid
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Midi Kits (QIAGEN, #12143) according to the manufacturer's
instructions.
Conﬁrmation of the deletion of miRNAs from MDV–BAC
The existence of the MDV genome and deletion of Meq-
clustered miRNAs or mdv1-miR-M4 from the GXΔMeq-miRs-
BAC and GXΔmiR-M4-BAC DNA was analyzed by PCR using
primers that amplify different viral genomic regions or genes
(primer pairs #3–9), kana resistance gene (primer pair #10),
and chicken ovotransferrin gene (primer pair #11) as shown in
Table S1. For further conﬁrmation, all corresponding PCR products
were conventionally cloned and sent to SangonBiotech Co., Ltd.
(Shanghai, China) for DNA sequencing.
Reconstitution and conﬁrmation of miRNA-deleted MDVs
For the rescue of MDV virus, the BAC DNA was transfected into
CEF using lipofectamine according to manufacturer's instructions
(Invitrogen). Brieﬂy, 1 mg DNA and 10 mL lipofectamine were each
diluted in 100 mL opti-MEM in separate tubes. The two solutions
were mixed gently and left at room temperature for 45 min, after
which the volume was increased to 1 mL. CEF were seeded into
6-well plates 1 day prior to transfection, and after washing the
monolayer twice with opti-MEM, the DNA/lipofectamine mixture
was added to each well. After incubating the cells at 37 1C for 6 h,
1 mL growth media was added to each well. The transfected cells
were incubated for several days until speciﬁc viral plaques
appeared. After passage for three rounds to enrich the viral titers,
GXΔMeq-miRs or GXΔmiR-M4 virus stocks were stored in liquid
nitrogen. As described above, the deletion of Meq-clustered
miRNAs or mdv1-miR-M4 from the viral genomes was analyzed
by PCR and corresponding products were cloned and sent for DNA
sequencing. Characterization of rescued viruses by indirect immu-
noﬂuorescence assay (IFA) was performed as described previously
(Sun et al., 2010).
Titration and in vitro proliferation of MDVs on CEFs
The plaque forming units (PFUs) of both GX0101 and miRNA-
deleted MDVs were measured using CEF monolayer cultures in 96-
well plates as described previously (Luo et al., 2011). To investigate
the in vitro virus proliferation rates, CEF monolayers on 6-well
plates were separately infected with 100 PFUs of GX0101 or
miRNA-deleted MDV viruses and sampled at 0, 24, 48, 72, 96,
120, and 144 h post-infection (hpi). DNA was extracted using
commercial DNA Extraction Kits (TaKaRa) and a real-time quanti-
tative PCR (qPCR) was performed, using the primers (primer pairs
#12–14 listed in Table S1) speciﬁc for MDV Meq, gB, and the
chicken ovotransferrin (OVO) gene was used as a reference gene
for normalization. Brieﬂy, ampliﬁcations were done using the
7500 Fast Real-Time PCR Systems (Applied Biosystems, Life Tech-
nologies, USA). The 20 mL PCR reactions contained 1 mL of template
DNA, 10 mM of each speciﬁc primer, and 2 SYBR Premix Ex
TaqTM (TaKaRa).The reaction sequence followed 50 1C for 2 min,
95 1C for 3 min, and 40 cycles of 95 1C for 15 s followed by 60 1C
for 1 min. The number of viral and OVO copies was estimated by
the use of a standard curve consisting of 10-fold serial dilutions of
plasmids containing either MDV gB or OVO genes. Since Meq gene
is found twice in the viral genome and the OVO gene is twice in a
diploid cell, quantiﬁcation of the MDV genome (copies per 106
cells) is expressed as the ratio of the numbers of Meq copies or
2 gB copies per 106copies of OVO gene.
Northern blotting analysis of miRNA expression
For analyzing the expression of mdv1-miR-M4 and other
miRNAs in the Meq-cluster, total cellular RNAs from CEFs infected
with GX0101, GXΔMeq-miRs or GXΔmiR-M4 virus were extracted
and the low-molecular-weight RNAs below 200 nucleotides in
length in the extracts were enriched, and then used for northern
blotting analysis of miRNA expression as described previously (Luo
et al., 2011). The corresponding DNA complementary oligonucleo-
tide to miRNAs (primers #15–19) and chicken U6 snRNA (primer
#20) is listed in Table S1.
Animal experiments
All experiments with chickens were conducted following the
protocols of the Ethical and Animal Welfare Committee of Key
Laboratory of Animal Immunology of the Ministry of Agriculture of
China. Three experimental groups, each consisting of 80 1-day-old
white Leghorn SPF chickens, were separately challenged with CEFs
containing 2000 PFUs of GX0101, GXΔMeq-miRs or GXΔmiR-M4
viruses by abdominal cavity inoculation. A fourth group of birds
(n¼80) was inoculated with an equal volume of mock infected
CEFs and served as negative controls. Post-challenge, birds were
inspected regularly for any clinical symptoms and mortality. At the
end of 90 days, all surviving birds were humanely euthanized and
their organs were examined for lesions at necropsy. The rates of
cumulative mortality and tumor generation were used to evaluate
the pathogenicity and oncogenicity of the virus mutants.
Determination of the viraemia
To ensure that infection was successful and to evaluate the
in vivo propagation of MDVs, the level of viraemia of MDV-
challenged chickens was monitored over the duration of the study.
Blood samples were collected in anticoagulant from three ran-
domly selected birds from each of the groups at 1, 3, 5, 7, 14, 21, 30,
45, 60, 75 and 90 days post-infection (dpi), and the determination
of the virus copy number was performed using a real-time qPCR as
described above.
Evaluation of effects of virus infection on body and organ weights
In order to evaluate the effects of virus infections on growth
rates, body weights of six birds randomly selected from each
group were obtained at 1, 3, 5, 7, 14, 21, 30, 45, 60, 75 and 90 dpi.
For determining the lymphoid organ weight, six birds from each
group were sacriﬁced on days 1, 3, 5, 7, 14, and 21 post-challenge
and its lymphoid organs (bursa and thymus) were collected and
weighed.
Pathological lesions and tumor induction by MDVs
At 30, 60, and 90 dpi, three birds from each experimental group
were randomly selected and humanely euthanized. Spleens and
livers were collected, ﬁxed in 10% formalin and processed for
embedding in parafﬁn. Thick sections of 4–7 mm of the tissues
were prepared and stained with hematoxylin and eosin (HE). After
staining, tissue sections were examined for lesions and tumor
deposits using a DM6000 light microscope (Leica, Germany).
Statistics
The differences in body weight, immune organ weight, mor-
tality, and tumor incidence between groups challenged with
different MDV strains were compared and analyzed by one way
Z.-H. Yu et al. / Virology 448 (2014) 55–64 63
analysis of variance (One way ANOVA, LSD) and were considered
signiﬁcant between groups at a probability level of po0.05.
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